“Revolutionizing STI Diagnosis: Roche’s cobas® Liat Molecular Tests Receive FDA Clearance with CLIA Waiver for Point-of-Care Testing”
Basel, 22 January 2025 – Roche Receives FDA Clearance for cobas® liat STI Multiplex Assay Panels Revolutionizing STI Diagnosis Roche, a global leader in healthcare, has made a significant breakthrough in the field of sexually transmitted infection (STI) diagnosis. The company announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance…